Belhaven Building - UMMC
Return to Locations Search
Address:
1405 N. State St.
Jackson, MS 39202
Parking:
Parking is available in the rear of the building.
Our Clinical Trials offered at this location:
Researchers at UMMC are committed to discovering innovative ways to prevent and treat the diseases that affect our daily lives. Clinical research studies play a vital role in the advancement of medicine and can improve the well-being of our families, friends, communities, and future generations. In this way, participation in clinical research studies furthers our vision to create "a healthier Mississippi."
Partnering with UMMC’s researchers may have many advantages, including:
- Gaining access to investigational treatments
- Increasing knowledge about your own health
- Giving the gift of improved health to our communities and future generations
- Contributing to the advancement of science by helping researchers learn more about how the human body and mind work or by helping find a cure or better treatments for diseases
| Clinical Trials | Publish Date | Description | ||||||
|---|---|---|---|---|---|---|---|---|
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's DiseaseIRB Number: 2019-0309
Published: January 08, 2020
View Locations
Clinical Trial Locations:
|
20200108094703 |
<div>Crohn's disease (CD) is a relapsing and remitting form of inflammatory bowel disease (IBD) that causes gastrointestinal signs and symptoms of diarrhea, abdominal pain, weight loss, and the passage of blood or mucous per rectum. The inflammation of CD can involve the mucosal surface of the gastrointestinal tract and penetrate through the full thickness of the gastrointestinal</div><div>wall, including the serosal surface. A need for safer, better tolerated, durable efficacious therapies for patients with CD exists. Despite significant uptake in the use of anti-TNF agents, tolerability of anti-TNFs due to allergic and autoimmune reactions, lack of durable response, and significant increased risk of infection remain problematic. Filgotinib is a once daily, oral therapy that may prove efficacious without the risk of allergic and autoimmune phenomena observed with anti-TNF agents.This is a long-term extension study to provide treatment with filgotinib for subjects with moderately to severely active CD (who have completed or met protocol specified efficacy</div><div>discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study for CD) for</div><div>144 weeks.</div> digestive conditions;digestion;pediatrics GS-US-419-3896 Olivia Henry scglover Digestive Conditions |
||||||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative ColitisIRB Number: 2020-0032
Published: February 21, 2020
View Locations
Clinical Trial Locations:
|
20200221155941 |
The objective of Study M14-675 (Phase 3 induction) is to evaluate the efficacy and safety of upadacitinib 45 mg once daily (QD) compared to placebo in inducing clinical remission (per Adapted Mayo score) in subjects with moderately to severely active ulcerative colitis (UC). digestion;digestive conditions M14-675 Yilianys Pride scglover Digestive Conditions |
||||||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis.IRB Number: 2020-0025
Published: February 21, 2020
View Locations
Clinical Trial Locations:
|
20200221154604 |
<div>This is a Phase 2b/3, multi center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of upadacitinib as</div><div>induction and maintenance therapy in subjects with moderately to severely active Ulcerative Colitis.</div><div>The study comprises 3 sub studies: a Phase 2b dose-ranging induction sub study (Sub study 1), a Phase 3 dose-confirming induction sub study (Sub study 2), and a Phase 3 maintenance sub study (Sub study 3).</div> digestive conditions;digestion 2016-000641-31 Yilianys Pride scglover Digestive Conditions |
||||||
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative ColitisIRB Number: 2020-0031
Published: February 21, 2020
View Locations
Clinical Trial Locations:
|
20200221155350 |
To evaluate the long-term safety and efficacy of upadacitinib in subjects with ulcerative colitis (UC) who have not responded at the end of the induction period in Study M14-234 Substudy 1, who have had loss of response during the maintenance period of Study M14-234 Substudy 3, or who have completed Study M14-234 Substudy 3. digestion;digestive conditions M14-533 Yilianys Pride scglover Digestive Conditions |
||||||
A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease Patient Optimization With ustEkinumab Re-induction POWER)IRB Number: 2019-0273
Published: December 04, 2019
View Locations
Clinical Trial Locations:
|
20191204160045 |
<div>This is a randomized, double-blind, placebo-controlled, multicenter, 24-week, Phase 3b study in adult patients with active moderate to severe Crohn's disease who initially responded to ustekinumab induction therapy per label followed, at any time, by secondary lost of response (LoR) to SC q8w ustekinumab maintenance therapy. The benefit of a single weight-tiered based IV re-induction dose of 6 mg/kg body weight ustekinumab versus continuous SC q8w maintenance treatment will be evaluated. <span style="font-size: 1rem; color: #0a0a0a;">This study is intending to evaluate the achievement of clinical response at Week 16 following a single IV re-induction dose of 6 mg/kg ustekinumab, compared with continuing regular SC q8w 90 mg ustekinumab administration, in participants with secondary loss of response (LoR) to SC q8w 90 mg ustekinumab maintenance therapy.</span></div> digestion;digestive conditions CNTO1275CRD3008 Yilianys Pride scglover Digestive Conditions |
||||||
A Randomized, Open-label, Phase 1b Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Signals of DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)IRB Number: 2019-0154
Published: August 22, 2019
View Locations
Clinical Trial Locations:
|
20190822153814 |
Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat is deposited in the liver. Two types of NAFLD are simple fatty liver (NAFL – nonalcoholic fatty liver), and nonalcoholic steatohepatitis (NASH). NASH is a form of NAFLD in which one will have inflammation of the liver and liver cell damage, in addition to and related to excess fat within the liver. It is the hope that DUR-928 can treat participants with NASH by reducing liver inflammation and liver cell damage, and so prevent development of scar tissue within the liver. preventive medicine C928-012 Amy Wigglesworth scglover Liver Diseases Preventive Medicine |
||||||
An-Open Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications.IRB Number: 2019-0268
Published: January 08, 2020
View Locations
Clinical Trial Locations:
|
20200108101514 |
<div>The proposed study will determine the effect of triple combination therapy with an anti-integrin (vedolizumab IV), a tumor necrosis factor (TNF), antagonist (adalimumab SC), and an immunomodulator (oral methotrexate) on endoscopic <span style="font-size: 1rem; color: #0a0a0a;">remission at Week 26 in Crohn's Disease (CD) subjects at higher risk for CD complications.</span></div> digestive conditions;digestion 009125 Yilianys Pride scglover Digestive Conditions |
||||||
Clinical and Pre-Clinical Predictors of Response to Gattex in Short Bowel SyndromeIRB Number: 2019-0325
Published: February 11, 2020
View Locations
Clinical Trial Locations:
|
20200211154947 |
Gattex is one FDA approved medication to treat short bowel syndrome. Gattex is known to promote mucosal growth and increase enterocyte mass. In this observational study, we will examine the innate lymphoid cells (ILCs) in blood and intestinal biopsies of subjects treated with Gattex. The study will collect historical medical records and biological samples. digestive conditions 2019-0325 Yilanys Pride sglover Digestive Conditions |
||||||
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's DiseaseIRB Number: 2019-0308
Published: January 08, 2020
View Locations
Clinical Trial Locations:
|
20200108095603 |
<div>Crohn's disease (CD) is a relapsing and remitting form of inflammatory bowel disease (IBD) that causes gastrointestinal signs and symptoms of diarrhea, abdominal pain, weight loss, and the passage of blood or mucous per rectum. The inflammation of CD can involve the mucosal surface of the gastrointestinal tract and penetrate through the full thickness of the gastrointestinal</div><div><br></div> digestion;digestive conditions GS-US-419-3895 Olivia Henry scglover Digestive Conditions |
||||||
Improving the Quality of Care for Adults with Inflammatory Bowel DiseaseIRB Number: 2019-0203
Published: July 07, 2020
View Locations
Clinical Trial Locations:
|
20200707134050 |
Demonstrate the impact of an Adult Inflammatory Bowel Disease (IBD) Learning Health System approach that enables patients and their care teams to co produce optimal health and high value care. digestion;digestive conditions 2019-0203 Yilanys Pride scglover Digestive Conditions |